Pfizer (NYSE:PFE) Sets New 12-Month High – Here’s What Happened

Pfizer Inc. (NYSE:PFE)’s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $30.15 and last traded at $30.0580, with a volume of 4,905,624 shares traded. The stock had previously closed at $29.44.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Healthcare-sector rotation is supporting PFE. Biotech and pharmaceutical stocks have held up relatively well as investors reduce exposure to technology and AI shares. Pfizer is being viewed as a value-and-income turnaround, with a forward P/E near 10 and a dividend yield around 5.8%. The Market Is Selling Off. Biotech and Pharma Aren’t.
• Positive Sentiment: Investors are responding to Pfizer’s turnaround narrative. Recent cancer-related approvals, an oncology alliance and expectations for portfolio improvements have strengthened the case that Pfizer can offset the decline in pandemic-era products. The stock has delivered a strong year-to-date return and is trading near its annual high. What Pfizer Bulls Got Right
• Neutral Sentiment: Analyst sentiment remains cautious. Wells Fargo and RBC Capital have maintained Hold ratings, indicating that Pfizer’s valuation and dividend are attractive but that the company still needs to demonstrate sustainable earnings growth. Pfizer Gets a Hold from Wells Fargo
• Neutral Sentiment: Elranatamab clinical progress is a potential pipeline catalyst. Pfizer has completed its Phase 2 MAGNETISMM-3 study, but the investment impact will depend on detailed results, regulatory progress and the drug’s commercial potential. Pfizer’s Elranatamab Trial Update
• Negative Sentiment: Dividend sustainability remains a concern. Commentary questioning whether Pfizer’s cash generation comfortably covers its dividend could limit enthusiasm for the stock, particularly while non-oncology revenue, vaccine demand and pricing trends remain important risks heading into the next quarterly report. Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Five equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.72.

Pfizer Trading Up 2.1%

The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market capitalization of $171.36 billion, a price-to-earnings ratio of 39.49, a PEG ratio of 2.01 and a beta of 0.32. The business has a 50 day simple moving average of $28.05 and a 200-day simple moving average of $26.57.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.7%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Onyx Bridge Wealth Group LLC lifted its stake in shares of Pfizer by 2.1% in the 3rd quarter. Onyx Bridge Wealth Group LLC now owns 49,253 shares of the biopharmaceutical company’s stock valued at $1,405,000 after purchasing an additional 1,006 shares during the period. Banque Pictet & Cie SA bought a new stake in shares of Pfizer during the 3rd quarter valued at about $252,000. James T. Borello RIA acquired a new stake in Pfizer during the third quarter worth approximately $56,000. Community Financial Services Group LLC grew its stake in Pfizer by 5.0% during the third quarter. Community Financial Services Group LLC now owns 15,775 shares of the biopharmaceutical company’s stock worth $444,000 after purchasing an additional 752 shares during the period. Finally, Fortitude Family Office LLC increased its holdings in Pfizer by 72.8% in the third quarter. Fortitude Family Office LLC now owns 2,148 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 905 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.